Paul Capital Partners has promoted Ken Macleod to partner. He is based in the firm's
PRESS RELEASE
Paul Capital Partners today announced that Ken Macleod, Ph.D., has been promoted to Partner. Based in Paul Capital's
“Since he joined Paul Capital four years ago, Ken has strengthened our presence in the European and Asian healthcare markets and helped us form many mutually beneficial partnerships,” said Walter Flamenbaum, M.D., a Partner of Paul Capital Partners. “He embodies our commitment to helping healthcare companies, institutions and inventors advance their goals by identifying strategic solutions to their financial and asset management needs. Ken's promotion to Partner reflects his demonstrated ability to identify promising healthcare investment opportunities and underscores Paul Capital's dedication to expanding its position in the global healthcare arena.”
Most recently, in April 2008, Paul Capital Healthcare invested up to $28 million in Plethora Solutions Holdings PLC and euro 18.4 million in Vernalis plc, both of which are based in the
“A growing number of European and Asian healthcare companies and institutions recognize that in order to realize their innovative potential they require an equally innovative approach to creating value and accessing capital,” said Dr. Macleod. “With more than $940 million committed to 37 healthcare investments, and similar leadership in the areas of private equity secondaries and venture capital funds of funds, Paul Capital provides funds that help leading-edge companies, institutions and individuals meet diverse strategic objectives. I am very pleased to become a partner of this highly regarded team.”
Dr. Macleod provides a strong operational background in the pharmaceutical and biotechnology industries, where he previously held senior management positions over a 15-year career at Serono, Abbott Laboratories and Beecham Pharmaceuticals. Prior to joining Paul Capital Partners, Dr. Macleod was a Venture Partner at Schroder Ventures Life Sciences where he was responsible for deal sourcing, evaluation and negotiation of pharmaceutical investment opportunities. Dr. Macleod earned his Ph.D. from the University of York, UK and his B.Sc. with honors in Biology from the University of Manchester, UK.
About Paul Capital Partners and Paul Capital Healthcare
Founded in 1991, Paul Capital manages $6.6 billion in capital commitments for its three investment platforms that include private equity secondaries, healthcare royalty and revenue interests, and venture capital fund of funds. The firm has offices in Hong Kong,
Through its funds, Paul Capital Healthcare is one of the largest dedicated healthcare investors globally, with more than $1.4 billion in equity capital commitments and debt facilities under management. Combined, the Paul Capital Healthcare funds have invested more than $940 million in the pharmaceutical, biotechnology, and medical device sectors. These investments are focused on commercial stage companies and products, and consist of investments in the form of royalties, revenue interests, debt and equity. Additional information on Paul Capital Healthcare can be found at www.paulcapitalhealthcare.com.
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: subscriptions@peimedia.com.